Kaplan–Meier survival analyses revealed that patients with higher HCP5-132aa levels had a higher risk of breast cancer-related death compared to patients with lower HCP5-132aa expression levels (Figure 2B,C, p < 0.0001, log-rank test). This evidence concerns the gene HCP5 and breast cancer.